Evidence map›Paper›PMID 38680666›Full record

ArticleRespirology case reports2024

Lemborexant-induced interstitial lung disease: A case report.

Satoshi Nakahara, Yumiko Ishii, Reika Egashira, Kazuya Tsubouchi, Mikihiro Kohno, Tomoyoshi Takenaka, Kentaro Tanaka, Isamu Okamoto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satoshi NakaharaDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.ORCID https://orcid.org/0009-0005-1205-5206
Yumiko IshiiDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Reika EgashiraDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Kazuya TsubouchiDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Mikihiro KohnoDepartment of Surgery and Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Tomoyoshi TakenakaDepartment of Surgery and Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Kentaro TanakaDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Isamu OkamotoDepartment of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the first case of drug-induced interstitial lung disease attributed to lemborexant. A 66-year-old man reported to our hospital with the acute onset of cough and breathlessness with ground-glass opacity on radiological examination. Symptoms were identified after taking lemborexant for 2 consecutive days. The patient had undergone lemborexant treatment 2 years prior and had exhibited no symptoms at that time. The drug-induced lymphocyte stimulation test for lemborexant was positive. He showed rapid improvement upon treatment with steroid. With the rise in prescriptions of lemborexant for insomnia, lemborexant should be considered as a possible cause of drug-induced interstitial lung disease.

Indexed as

drug‐induced interstitial lung diseaselemborexantorexin receptor antagoniststype IV hypersensitivity reactions

Identifiers

PMID38680666
PMCPMC11045439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.